Priming Lines With Drug May Reduce Hypersensitivity Reactions From Rituximab

Elisa Becze BA, ELS, Editor


Monoclonal antibody cancer treatments such as rituximab have a high risk for hypersensitivity reactions (HSR) from cytokine release syndrome. The symptoms, which can range from mild to life threatening, result from tumor antigen-expressing cells releasing cytokines (e.g., tumor necrosis factor, interleukin, interferon) into the blood as they are destroyed. Symptoms include fever, chills, rigors, rash, headache, hypotension, shortness of breath, bronchospasm, nausea, vomiting, and abdominal pain.

View Article @

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles